We are live on ! Find out more
PCYC

Pharmacyclics
PCYC

Delisted

PCYC was delisted on the 22nd of May, 2015.

2 hedge funds and large institutions have $124K invested in Pharmacyclics in 2016 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
+2
Holders Change %
–
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Sellers

No sellers this quarter

PCYC Hedge Fund Activity: Q1 2016 in Review

2 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Pharmacyclics (PCYC) for Q1 2016, worth a combined $124K.

Buyers outnumbered sellers: 2 funds opened new PCYC positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Mizuho Asset Management, opening a new position worth an estimated $99K.

  • 2 institutional investors held Pharmacyclics (PCYC) as of Q1 2016, up from 0 in Q4 2015.
  • Funds reported $124K of Pharmacyclics stock for Q1 2016.
  • 2 funds opened new Pharmacyclics positions in Q1 2016 and 0 closed out, a net change of +2 holders.
  • The largest Pharmacyclics buyer in Q1 2016 was Mizuho Asset Management, an estimated $99K added.

Based on aggregated 13F filings for Q1 2016.